Immune and neurohormonal pathways in chronic heart failure

Congestive Heart Failure

Volumn 8, Issue 1, 2002, Pages 23-48

  Sharma, Rakesh ^a   Anker, Stefan D ^a  

^a Clinical Cardiolology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NORADRENALIN; PRASTERONE; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

CACHEXIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENERGY METABOLISM; HEART FAILURE; HORMONE ACTION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MAJOR CLINICAL STUDY; OXYGEN CONSUMPTION; PATHOGENESIS; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0036232446     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2002.00724.x     Document Type: Review

References (82)

1. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines
2. The neuroendocrine and sympathetic nervous system in congestive heart failure
3. Wasting as independent risk factor for mortality in chronic heart failure
4. Insights into the pathogenesis of chronic heart failure: Immune activation and cachexia
5. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
6. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart
7. The cardiovascular response of normal humans to the administration of endotoxin
8. Expression and functional significance of tumor necrosis factor receptors in human myocardium
9. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
10. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance
11. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantely acute cachexia
12. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure
13. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death
14. Tumour necrosis factor in chronic heart failure: A peripheral view on pathogenesis, clinical manifestations and therapeutic implications
15. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure
16. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure
17. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: Implications for clinical trials
18. Hyperleptinaemia in chronic heart failure. Relationships with insulin
19. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure
20. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure
21. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure
22. Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure
23. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy
24. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness
25. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
26. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
27. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
28. Proinflammatory cytokines measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease
29. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy
30. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
31. Loss of bone mineral in patients with cachexia due to chronic heart failure
32. Plasma cytokine parameters and mortality in patients with chronic heart failure
33. Prognostic value of serum cytokines in patients with congestive heart failure
34. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation
35. Uric acid in chronic heart failure: A marker of chronic inflammation
36. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors
37. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium
38. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure
39. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure
40. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy
41. Elevated tumor necrosis factor alpha of blood mononuclear cells in patients with congestive heart failure
42. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
43. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration
44. Systemic inflammation in patients with heart failure
45. How are cytokines activated in heart failure?
46. Neurohormonal mechanisms involved in congestive heart failure
47. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme
48. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
49. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
50. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
51. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure
52. Catecholamine levels and treatment in chronic heart failure
53. Increased resting metabolic rate in patients with congestive heart failure
54. Insulin resistance in chronic heart failure
55. Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure
56. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease
57. Tumor necrosis factor alpha: A key component of the obesity-diabetes link
58. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation
59. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy
60. A placebo-controlled study of growth hormone in patients with congestive heart failure
61. Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting
62. The endocrine system and the immune response: Prospects for novel therapeutic approaches
63. Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure
64. High-versus low-dose ACE inhibition in chronic heart failure: A double-blind, placebo-controlled study of imidapril
65. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy
66. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure
67. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure
68. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure
69. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
70. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor
71. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses
72. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent
73. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing
74. Immunomodulation: A new horizon for medical treatment of heart failure
75. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy-lessons from animal experiments
76. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis
77. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain
78. Denopamine, a betaladrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: Suppression of tumor necrosis factor-alpha production in the heart
79. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure
80. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats
81. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro
82. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure